UBS Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-120,549
| Closed | -$1.16M | – | 11047 |
|
|
2024
Q4 | $1.16M | Buy |
120,549
+50,832
| +73% | +$265K | ﹤0.01% | 5196 |
|
|
2024
Q3 | $199K | Buy |
69,717
+16,094
| +30% | +$49.8K | ﹤0.01% | 5876 |
|
|
2024
Q2 | $157K | Sell |
53,623
-21,723
| -29% | -$59.4K | ﹤0.01% | 5837 |
|
|
2024
Q1 | $240K | Buy |
75,346
+8,394
| +13% | +$28K | ﹤0.01% | 5716 |
|
|
2023
Q4 | $225K | Buy |
66,952
+31,144
| +87% | +$80.2K | ﹤0.01% | 5715 |
|
|
2023
Q3 | $85.2K | Sell |
35,808
-3,408
| -9% | -$7.14K | ﹤0.01% | 5938 |
|
|
2023
Q2 | $69K | Buy |
39,216
+27,203
| +226% | +$69.5K | ﹤0.01% | 6280 |
|
|
2023
Q1 | $37K | Buy |
12,013
+7,840
| +188% | +$47K | ﹤0.01% | 6646 |
|
|
2022
Q4 | $22.1K | Buy |
+4,173
| New | +$19.1K | ﹤0.01% | 7551 |
|
|
2022
Q1 | – | Sell |
-9,795
| Closed | -$67K | – | 11054 |
|
|
2021
Q4 | $67K | Buy |
+9,795
| New | +$66.7K | ﹤0.01% | 6669 |
|
|
2021
Q3 | – | Sell |
-2,000
| Closed | -$20K | – | 10221 |
|
|
2021
Q2 | $20K | Sell |
2,000
-115,782
| -98% | -$1.04M | ﹤0.01% | 7348 |
|
|
2021
Q1 | $1.13M | Buy |
117,782
+9,706
| +9% | +$95.2K | ﹤0.01% | 4133 |
|
|
2020
Q4 | $1.19M | Buy |
108,076
+1,991
| +2% | +$21K | ﹤0.01% | 3872 |
|
|
2020
Q3 | $941K | Buy |
+106,085
| New | +$1.21M | ﹤0.01% | 3689 |
|
Other funds holding PSTX
UBS Group's PSTX Position: Q1 2025 in Review
UBS Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 120,549 shares — an estimated $1.16M sold.
UBS Group first reported a position in PSTX in Q3 2020 and held it in 14 quarters. The position peaked at $1.19M in Q4 2020. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- UBS Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 120,549 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.16M.
- UBS Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 14 quarters.
- UBS Group's Poseida Therapeutics, Inc. Common Stock position peaked at $1.19M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.